Journey Medical

Journey Medical announced FDA approval of Emrosi™ for rosacea treatment, highlighting its potential as a best-in-class oral medication. Supported by positive Phase 3 trial results, Emrosi showed superiority over current treatments. Journey Medical plans a U.S. launch in 2025, aiming to establish Emrosi as a new standard of care for rosacea.

Emrosi, a minocycline hydrochloride extended-release capsule, treats rosacea in adults by reducing inflammatory lesions. Approved by the FDA on November 4, 2024, it may cause serious side effects like skin reactions, liver problems, and tooth discoloration. Not recommended for children under 18 or during pregnancy and breastfeeding. Dosage is 40 mg once daily, with precautions against sunlight exposure and interactions with other drugs.

Journey Medical Corporation's EMROSI, formerly DFD-29, FDA-approved for rosacea treatment, contains 40 mg minocycline. Outperformed Doxycycline 40mg in trials. Available Q1/Q2 2025. Details at emrosi.com.

FDA approves Emrosi, a 40 mg minocycline hydrochloride extended release capsule, for rosacea treatment in adults, supported by two phase 3 trials showing superiority over placebo and Oracea.

FDA approves minocycline hydrochloride extended-release capsules (Emrosi) for treating rosacea in adults, supported by phase III trials showing higher treatment success rates compared to doxycycline and placebo. Common adverse event is dyspepsia. Expected availability in H1 2025.

Journey Medical announces FDA approval of Emrosi™ (Minocycline Hydrochloride Extended Release Capsules, 40 mg) for treating rosacea in adults, developed with Dr. Reddy's Laboratories Ltd. Emrosi demonstrated superiority over standard-of-care and placebo in Phase 3 trials, with initial U.S. market supply expected in Q1 or Q2 2025.

Journey Medical Corporation announced FDA approval of minocycline hydrochloride, 40 mg extended release capsules (Emrosi) for treating erythema and inflammatory lesions in rosacea patients. Supported by positive phase 3 trial data, Emrosi demonstrated efficacy and tolerability, with no significant adverse effects, positioning it as a best-in-class oral therapy for rosacea symptoms. The drug is expected to be available in Q1 or Q2 2025.

FDA approves minocycline hydrochloride modified release capsules 40 mg (Emrosi) for rosacea treatment, following successful phase 3 clinical trials. Emrosi demonstrated superior efficacy and safety compared to doxycycline and placebo, with significant reductions in inflammatory lesions and erythema.

The FDA approved minocycline hydrochloride modified release capsules 40 mg (Emrosi) for treating rosacea's inflammatory lesions and erythema, following positive phase 3 trials. The drug showed superior efficacy and safety over placebo and doxycycline, with significant reductions in lesion count and erythema, marking a significant advancement in rosacea treatment.

Journey Medical announced FDA approval of Emrosi for rosacea treatment in adults, developed with Dr. Reddy's Laboratories. Initial U.S. supply expected Q1-Q2 2025, to be commercialized by Journey Medical's dermatology-focused team.